

**To:** Minister van VWS [5.1.2e]@minvws.nl]  
**Cc:** [5.1.2e], [5.1.2e], [5.1.2e]@astrazeneca.com]  
**From:** [5.1.2e], [5.1.2e]  
**Sent:** Mon 11/23/2020 7:18:39 AM  
**Subject:** AstraZeneca/Oxford AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19  
**Received:** Mon 11/23/2020 7:18:54 AM  
[AZD1222 HLR RNS FINAL.pdf](#)

Dear Minister De Jonge, Minister Van Ark,

We are pleased to inform you that AstraZeneca has just announced positive high-level results from an interim analysis of AZD1222 trials in the UK and Brazil. The data show that the vaccine was highly effective in preventing COVID-19 infection, the primary endpoint, with no hospitalisations or severe cases of the disease reported in participants receiving the vaccine.

Two different dosing regimens demonstrated efficacy with one showing a better profile. One dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart. No serious safety events related to the vaccine have been confirmed and AZD1222 was well tolerated across both dosing regimens. The full analysis of the interim results is being submitted for publication in a peer-reviewed journal. AstraZeneca will now immediately prepare regulatory submission of the data to authorities around the world.

Today marks an important milestone in our fight against the pandemic. This vaccine's efficacy and safety confirm that it will have an immediate impact on this public health emergency, reducing hospitalisations and saving lives. The vaccine can be stored, transported and handled at 2-8 °C (about 34-42 °F) for at least six months, enabling easy use within existing healthcare settings. Meanwhile, the promise of the low dose regimen means that through our existing agreement with the European Commission to provide up to 400 million doses of AZD1222 vaccine across the EU, our dose capacity could potentially go further, and more people could be vaccinated quickly in Europe and around the world.

Please find attached the official company announcement with further information.

We would like to thank you for your continued partnership and would welcome the opportunity to speak with you to discuss today's announcement in greater detail.

Best regards,

[5.1.2e]

AstraZeneca

M: [5.1.2e] [5.1.2e]  
[5.1.2e]@astrazeneca.com

[5.1.2e] T: +31 [5.1.2e]  
[5.1.2e]@astrazeneca.com

---

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at [www.astrazeneca.com](http://www.astrazeneca.com)